Fractal dimension brain analysis has enable to show the differences between healthy people’s brain and patients with neurological diseases, such as:
Therefore, Fractalmed® analysis is highly useful to support the diagnosis of the disease and likely to monitor the development of it.
Nowadays, we are assessing the capacity of Fractalmed to be used as a prognosis biomarker or predictive biomarker de respuesta al tratamiento, lo que permitirá ayudar en la toma de desiciones clínicas respecto al manejo de la enfermedad.
To this effect, Fractalmed® will request the CE marking in order to be used in support of clinical diagnosis.
Clinically isolated syndrome patients type show changes on the FD of the white and grey matter in normal appearing before damages appear.
Some changes have been detected in the brain FD imaging of patients with other neurological diseases, such as Schizophrenia, Alzheimer and Parkinson amongst others.
FD varies significantly depending on the type of MS, so it allows for parametrization of the monitoring, and therefore the tracking of the disease.
A change in the FD of brain structures while using resonance imaging of normal individuals during their aging has also been revealed.
We have obtained results regarding detection of brain disorder in premature infants who suffered intrauterine growth restriction and premature birth even when the brain imaging was appearing normal.
It has been found that the FD allows the monitoring of neuroradiological brain tumors with antiangiogenic treatments.
Software
Fractal dimension brain analysis has enable to show the differences between healthy people’s brain and patients with neurological diseases, such as: